Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

  1. Musolino, A.
  2. Campone, M.
  3. Neven, P.
  4. Denduluri, N.
  5. Barrios, C.H.
  6. Cortes, J.
  7. Blackwell, K.
  8. Soliman, H.
  9. Kahan, Z.
  10. Bonnefoi, H.
  11. Squires, M.
  12. Zhang, Y.
  13. Deudon, S.
  14. Shi, M.M.
  15. André, F.
Journal:
Breast Cancer Research

ISSN: 1465-542X,  1465-5411

Year of publication: 2017

Volume: 19

Issue: 1

Type: Article

DOI: 10.1186/S13058-017-0807-8 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus